Teva’s Cubicin Authorized Generic Is First Rival To Merck’s Brand
Executive Summary
Teva launched an authorized generic version of Merck’s blockbuster antibiotic, while Pfizer did not provide an update on the timeline of a generic launch for which a court decision paved the way.
You may also be interested in...
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
The world’s generic drug leader has cemented its leadership position for the foreseeable future with the acquisition of Allergan’s generics business. Management outlined how it plans to grow the combined business by taking advantage of its size during an investor briefing.
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.